(HNGE) Hinge Health - NYSE
Sector: Healthcare | Industry: Health Information Services | Exchange: NYSE (USA) | Market Cap: 5.463m USD | Total Return: 68.7% in 12m
Total Rating 25
Safety 29
Buy Signal 1.85
Market Cap:
5.46B
Avg Turnover: 119M
Avg Turnover: 119M
Risk 3d forecast
Volatility-%
VaR 5th Pctl-%
VaR vs Median-%
Reward TTM
Sharpe Ratio1.07
Rel. Str. IBD92.3
Rel. Str. Peer Group75.9
Character TTM
Beta
Beta Downside-0.247
Hurst Exponent0.581
Drawdowns 3y
Max DD0.00%
CAGR/Max DD0.00
CAGR/Mean DD0.00
EPS (Earnings per Share)
Qual. Beats: 0
Revenue
Rev. CAGR: 41.71%
Rev. Trend: 99.5%
Rev. Trend: 99.5%
Qual. Beats: 0
Warnings
Altman Z'' -7.85 < 1.0 - financial distress zone
Tailwinds
Supp Ema8, Rs Leader, Confidence
Description: HNGE Hinge Health
Hinge Health, Inc. focuses on building a health system that scales and automates the delivery of care using technology. It designs its platform to address musculoskeletal system care (MSK), including acute injury, chronic pain, and post-surgical rehabilitation. The company also provides personalized and automated MSK care through AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device. It primarily serves self-insured employers. The company was founded in 2012 and is headquartered in San Francisco, California.
Headlines to Watch Out For
Piotroski VR-10 (Strict)
5.5
| Net Income: -510.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 14.13 > 1.0 |
| NWC/Revenue: 14.09% < 20% (prev 81.29%; Δ -67.20% < -1%) |
| CFO/TA 0.29 > 3% & CFO 209.6m > Net Income -510.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.4m) vs 12m ago 5.61% < -2% |
| Gross Margin: 80.83% > 18% (prev 79.30%; Δ 1.53% > 0.5%) |
| Asset Turnover: 89.69% > 50% (prev 60.56%; Δ 29.13% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
Altman Z''
-7.85
| A: 0.12 (Total Current Assets 505.5m - Total Current Liabilities 414.5m) / Total Assets 728.8m |
| B: -1.39 (Retained Earnings -1.02b / Total Assets 728.8m) |
| C: -0.73 (EBIT TTM -526.2m / Avg Total Assets 720.7m) |
| D: 0.75 (Book Value of Equity 311.6m / Total Liabilities 417.2m) |
| Altman-Z'' = -7.85 = D |
Beneish M
-1.85
| DSRI: 1.01 (Receivables 114.9m/75.9m, Revenue 646.3m/431.5m) |
| GMI: 0.98 (GM 79.30% / 80.83%) |
| AQI: 2.56 (AQ_t 0.28 / AQ_t-1 0.11) |
| SGI: 1.50 (Revenue 646.3m / 431.5m) |
| TATA: -0.99 (NI -510.3m - CFO 209.6m) / TA 728.8m) |
| Beneish M = -1.85 (Cap -4..+1) = B |
What is the price of HNGE shares?
As of June 26, 2026, the stock is trading at USD 75.14 with a total of 2,499,021 shares traded. Over the past week, the price has changed by +12.08%, over one month by +41.83%, over three months by +86.96% and over the past year by +68.74%.
Current recommended Stop Loss: 71.10 (which is 5.4% or 1.3 ATR below the current price).
Is HNGE a buy, sell or hold?
Hinge Health has no consensus analysts rating.
What are the forecasts/targets for the HNGE price?
| Analysts Target Price | 79.7 | 6.1% |
Hinge Health (HNGE) - Fundamental Data Overview
as of 26 June 2026
Market Cap USD = 5.46b (5.46b USD * 1.0 USD.USD)P/E Forward = 29.7619
P/S = 8.4528
P/B = 48.8865
Revenue TTM = 646.3m USD
EBIT TTM = -526.2m USD
EBITDA TTM = -521.9m USD
Long Term Debt = 2.73m USD (estimated: total debt 6.97m - short term 4.23m)
Short Term Debt = 4.23m USD (from shortTermDebt, last quarter)
Debt = 6.97m USD (from shortLongTermDebtTotal, last quarter) (leases 6.97m already included)
Net Debt = -310.3m USD (calculated: Debt 6.97m - CCE 317.3m)
Enterprise Value = 5.15b USD (5.46b + Debt 6.97m - CCE 317.3m)
Interest Coverage Ratio = unknown (Ebit TTM -526.2m / Interest Expense TTM 0.0)
EV/FCF = 35.27x (Enterprise Value 5.15b / FCF TTM 146.1m)
FCF Yield = 2.84% (FCF TTM 146.1m / Enterprise Value 5.15b)
FCF Margin = 22.61% (FCF TTM 146.1m / Revenue TTM 646.3m)
Net Margin = -78.95% (Net Income TTM -510.3m / Revenue TTM 646.3m)
Gross Margin = 80.83% ((Revenue TTM 646.3m - Cost of Revenue TTM 123.9m) / Revenue TTM)
Gross Margin QoQ = 84.60% (prev 84.45%)
Tobins Q-Ratio = 7.07 (Enterprise Value 5.15b / Total Assets 728.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 6.97m)
Taxrate = 2.26% (814k / 35.9m)
NOPAT = -514.3m (EBIT -526.2m * (1 - 2.26%)) [loss with tax shield]
Current Ratio = 1.04 (Total Current Assets 505.5m / Total Current Liabilities 484.0m)
Debt / Equity = 0.02 (Debt 6.97m / totalStockholderEquity, last quarter 311.6m)
Debt / EBITDA = 0.59 (negative EBITDA) (Net Debt -310.3m / EBITDA -521.9m)
Debt / FCF = -2.12 (Net Debt -310.3m / FCF TTM 146.1m)
Total Stockholder Equity = 367.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -70.81% (Net Income -510.3m / Total Assets 728.8m)
RoE = -138.7% (Net Income TTM -510.3m / Total Stockholder Equity 367.9m)
RoCE = -142.0% (out of range, set to none) (EBIT -526.2m / Capital Employed (Equity 367.9m + L.T.Debt 2.73m))
RoIC = -179.7% (out of range, set to none) (NOPAT -514.3m / Invested Capital 286.2m)
WACC = 0.0% (E(5.46b)/V(5.47b) * Re(0.0%) + D(6.97m)/V(5.47b) * Rd(0.0%) * (1-Tc(0.02)))
Discount Rate = 5.29% (= Risk Free + ERP)
Shares (quarterly) Correlation: 54.90 | Cagr: 2.46%
[DCF] Terminal Value 77.97% ; FCFF base≈104.5m ; Y1≈119.8m ; Y5≈176.4m
[DCF] Fair Price = 54.24 (EV 2.65b - Net Debt -310.3m = Equity 2.96b / Shares 54.7m; r=8.35% [Cost of Equity (WACC unavailable) [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.50 | Revenue CAGR: 41.71% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.61 | Chg30d=+2.18% | Revisions=+71% | Analysts=12
EPS next Quarter (2026-09-30): EPS=0.68 | Chg30d=+3.86% | Revisions=+71% | Analysts=12
EPS current Year (2026-12-31): EPS=2.57 | Chg30d=+2.66% | Revisions=+73% | GrowthEPS=-1.9% | GrowthRev=+39.0%
EPS next Year (2027-12-31): EPS=3.34 | Chg30d=+7.08% | Revisions=+75% | GrowthEPS=+30.0% | GrowthRev=+25.0%
[Analyst] Revisions Ratio: +75%